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Substantial data indicate that amyloid-β (Aβ), the major component of senile plaques, plays a central role in Alzheimer’s
Disease and indeed the assembly of naturally occurring amyloid peptides into cytotoxic aggregates is linked to the
disease pathogenesis. Although Aβ42 is a highly aggregating form of Aβ, the co-occurrence of shorter Aβ peptides might
affect the aggregation potential of the Aβ pool. In this study we aimed to assess whether the structural behavior of
human Aβ42 peptide inside the brain is influenced by the concomitant presence of N-terminal fragments produced by
the proteolytic activity of glial cells. We show that the occurrence of the human C-terminal truncated 1–24 Aβ fragment
impairs Aβ42 clearance through blood brain barrier and promotes the formation of Aβ42 aggregates even in the healthy
brain. By showing that Aβ1-24 has seeding properties for aggregate formation in intracranially injected wild type mice,
our study provide the proof-of-concept that peptides produced upon Aβ42 cleavage by activated glial cells may cause
phenotypic defects even in the absence of genetic mutations associated with Alzheimer’s Disease, possibly contributing
to the development of the sporadic form of the pathology.
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Alzheimer’s disease (AD) is a protein misfolding pathology,
caused by accumulation of abnormally folded Aβ and tau
polypeptides, which form amyloid plaques and neurofibril-
lary tangles in the brain of affected individuals. Aβ
aggregates have been linked with learning and memory
deficits in both human and mouse models of the disease,
making Aβ deposition a target for prevention and treat-
ment [1–3]. In the last years, a lot of effort has been
focused on the identification of the processes leading to Aβ
aggregation. Evidence have indicated that, although Aβ42 is
a highly aggregating form of Aβ [4, 5], the co-occurrence of
Aβ peptides with different length can affect the neurotoxic
and aggregation potential of the Aβ pool (reviewed in [6]).
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(http://creativecommons.org/publicdomain/zeshown to represent an important factor in initializing Aβ
fibrillogenesis and toxicity [7], indicating that the presence
of different Aβ forms may affect the development of AD
in vivo.
Consistently, while small amounts of Aβ-containing
brain extracts, deriving from either AD patient or AD
transgenic mouse, induce β-amyloidosis and glial activa-
tion once intracranially injected in pre-depositing AD
transgenic mice [8–11], the chronic infusion of soluble,
synthetic Aβ42 peptides into wild type (wt) rodent
brains does not result in amyloid deposition [9]. The
finding that Aβ42 alone fails to show seeding properties
in the healthy brain and does not trigger pathogenetic
pathways indicates the occurrence of efficient clearance
mechanisms and suggests that brain-specific cofactors,
specifically present in pathological conditions, are
needed for effective seeding [9].
Although aggregation properties of full length Aβ42
have been deeply explored both in vitro and in vivo,
much less is known about the in vivo aggregating prop-
erties of shorter Aβ fragments. This aspect may bele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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of different length are largely produced by the proteo-
lytic activity of glial cells during the development of
AD [12]. Indeed, several proteases including neprilysin
[13], insulin-degrading enzyme [14], endothelin-converting
enzyme [15], angiotensin-converting enzyme [16] and
matrix metalloproteinase-9 (MMP9) [17–20] have been
shown to degrade soluble Aβ in vitro, acting at specific
cleavage sites and generating characteristic Aβ fragments.
These proteolytic activities, therefore, are critical in deter-
mining the quantitative and qualitative pattern of cerebral
Aβ levels ([21]; reviewed in [22]). MMP9 in particular,
which generates different C-terminal truncated Aβ frag-
ments, including 1–16, 1–20, 1–23, 1–30, 1–33 and 1–34
[19, 23], is thought to play relevant roles in different patho-
logical contexts, as suggested by the observation that its ex-
pression can be stimulated by diverse insults, including Aβ
itself [24], and is up-regulated in glia cells adjacent to amyl-
oid deposits [25].
Since Aβ N-terminal fragments of varying lengths are
expected to exhibit different physico-chemical properties
which may result in different aggregation behaviors, as
also indicated by modeling of aggregation determinants
with bioinformatics methods [26], we aimed to investigate
whether dynamics of interaction and structural behavior
of human Aβ42 peptide inside the brain are influenced by
the concomitant presence of C-terminal truncated frag-
ments. We took advantage of the commercially available
synthetic human Aβ1-24 peptide (referred to as Aβ24), a
C-terminal truncated Aβ fragment overlapping with
MMP9 cleavage products (residues 1–20 and 1–23, [20])
and coincides with a turn region between β-sheets in
recently-resolved fibrillar structures. Our results indicate
that the presence of Aβ24 in intracranially injected wild
type mice impairs Aβ42 clearance and promotes forma-
tion of Aβ42 aggregates even in the healthy brain.
Results
Synthetic Aβ24 fragments promote aggregates formation
in wt mice brain
Three month-old wt mice were intracranially (i.c.)
injected with either the oligomeric form of the single H-
Aβ42 peptide or with an equimolar mixture of oligo-
meric H-Aβ42 and H-Aβ24 peptides, and the brains
were examined after 2.5 or 6 months (see cartoon,
Fig. 1h). As previously described [9], H-Aβ42 injected in
the brain of wt mice and examined 6 months later did
not cause Aβ deposition. H-Aβ24, and even more po-
tently H-Aβ42/H-Aβ24 mix, induced the formation of
aggregates, detected with the Aβ N-terminal specific
antibody 6E10, followed by HRP (Fig. 1a and e). 6E10-
positive aggregates were already detectable 2.5 months
after injection of H-Aβ24 or H-Aβ42/H-Aβ24 mix in the
mice brains (Fig. 1b and d). Aggregates were alsodetectable by the amyloidogenic dye Congo red both 2.5
and 6 months after injection (Fig. 1c and f, g). Consist-
ently, the highest number of Congo red positive aggre-
gates was detected in the brains of mice injected with
H-Aβ42/H-Aβ24 mix (Fig. 1f and g).
As a further confirmation for the formation of amyloi-
dogenic aggregates, brain sections from mice i.c. injected
and incubated for 2.5 months were stained with thiofla-
vin T (ThT), a benzothiazole dye that exhibits enhanced
fluorescence upon binding to amyloid fibrils [27, 28].
ThT-positive aggregates were detected in wt mice brain
injected with H-Aβ24 or with H-Aβ42/H-Aβ24 mix
(Fig. 2a and c); both ThT- (Fig. 2a) and 6E10- (Fig. 2b)
positive aggregates were surrounded by microglia, as re-
vealed by Iba1 staining (Fig. 2a and b, red staining).
Again, no ThT positive aggregates were detected in
vehicle-injected wt mice, whereas only ThT-positive
blood vessels, which are not surrounded by microglia,
were visible in wt mice injected with H-Aβ42 (Fig. 2a,
arrows). The recruitment of microglia around aggregates
was reminiscent of the plaques present in APP/PS1 trans-
genic mice brain (Fig. 2b, right). Consistent with data
reported in AD patients and mice models [29–33], a
significant increase in the levels of tumor necrosis factor-
alpha (TNF-alpha) was detected by ELISA in the serum
and brains of mice i.c. injected with H-Aβ24 and of H-
Aβ42/H-Aβ24 mix, and much less with H-Aβ42 alone
(Fig. 2d and e). These data indicate that H-Aβ24 and, even
more prominently, H-Aβ42/H-Aβ24 mix induce an
inflammatory reaction in the brain of injected mice.
Interestingly, 6 months after i.c. injection, few scattered
6E10-positive spots also start to become detectable in the
non-injected side (Fig. 3a and b), suggesting a possible
spreading of misfolded/aggregating Aβ. Also, amyloid ag-
gregates were detectable at the hippocampal level in the
injected hemisphere (Fig. 3c).
Behavioral deficits in wt mice injected with Aβ24 peptide
To investigate whether the formation of Aβ aggregates
and the increase in TNF-alpha were accompanied by the
occurrence of cognitive defects [34–36], mice were ana-
lysed using 3 different behavioral tests: the open field, a
recognized paradigm for assessing motor activity and
anxiety-like behaviors in response to a novel environ-
ment [37–39]; the sociality task, which also unveils anx-
ious and aggressive behaviors; and the novel object
recognition (NOR), that, monitoring the time spent by
mice to explore a novel object, enables the assessment
of possible declines in learning and memory. Consist-
ently with literature data [40], 6 months old APP/PS1
mice displayed significant hyperactivity and anxiety com-
pared to the wt littermates, as shown by both the open
field and sociality tasks (Fig. 4a–f ). Interestingly, wt mice
injected with the mix of the two peptides displayed
Fig. 1 (See legend on next page.)
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Fig. 2 Intracranial injection of H-Aβ24 and H-Aβ42/H-Aβ24 mix in wt mice induces microglia recruitment and TNF-alpha production. a Immunofluorescence
staining of ThT-positive aggregates (green) surrounded by Iba1 positive microglia cells (red) in wt mice brain slice 2.5 months after injection of vehicle, H-Aβ42,
H-Aβ24 or H-Aβ42/H-Aβ24 mix. Arrows in H-Aβ42 panel indicate Aβ accumulation in vessels. Scale bar: 10 μm. b IF staining of 6E10 positive aggregates (blue)
surrounded by Iba1 positive microglia cells (red) in wt mice brains 2.5 months after injection of vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/H-Aβ24 mix. IF staining of
6E10 positive plaques and surrounding microglia are shown in a brain section of 8 months old APP/PS1 transgenic mouse for comparison. Scale bar: 10 μm.
c Quantification of ThT-positive plaques in sections of wt mice brains 2.5 months after injection of vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/H-Aβ24 mix. Aβ
detected in correspondence of blood vessels (H-Aβ42 left panel, arrows) was excluded from the analysis. 6 sections were analyzed for each mouse brain
(N=3 mice for each group). Statistical analysis was performed by One way Anova, Bonferroni multiple comparison test (*** P<0.001). d and e TNF-alpha
levels measured by ELISA in brain homogenates d and serum e of wt mice 2.5 months after the injection of vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/H-Aβ24
mix. Statistical analysis was performed by One way Anova, Bonferroni multiple comparison test (*** P< 0.001; ** P<0. 01)
(See figure on previous page.)
Fig. 1 Intracranial injection of H-Aβ24 and H-Aβ42/H-Aβ24 mix in wt mice induces amyloid aggregate deposition. a 6E10 DAB staining of hippocampal
brain sections 6 months after vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/H-Aβ24 mix injection. Sagittal plane sections are shown on the left; middle and right
panels show enlargements of the dorsal cerebral cortex. 6E10-immunopositive aggregates are visible on a cresyl violet-luxol fast blue counterstaining. Scale
bars: left 1 mm, middle 100 μm, right 50 μm. b 6E10 DAB staining of brain sections 2.5 months after vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/H-Aβ24 mix
injection. Scale bar: 50 μm. c Congo red staining of brain sections 2.5 months after the injection of vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/H-Aβ24 mix. On the
right, representative images of aggregates detected 6 months after H-Aβ42/H-Aβ24 mix injection are shown. Top: bright field images; bottom: epifluorescence
images -FITC filter. Scale bar: 50 μm. d and e Quantification of 6E10 DAB positive plaques 2.5 or 6 months after the injection of vehicle, H-Aβ42, H-Aβ24 or H-
Aβ42/H-Aβ24 mix. 6 brain sections were analyzed for each mice (N= 3 mice for each group). Statistical analysis was performed by One way Anova, Bonferroni
multiple comparison test (****P< 0.0001; ***P< 0.001). f and g Quantification of Congo red-positive plaques area (μm2) per brain section at 2.5 or 6 month
after injection. 10 sections of 50 μm thickness per slice were analyzed for each mouse brain (N= 6 mice for each group). Statistical analysis was performed by
One way Anova, Bonferroni multiple comparison test (**P< 0.01). h Cartoon depicting the experimental scheme
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Fig. 3 Intracranial injection of H-Aβ42/H-Aβ24 mix in wt mice induces spreading of misfolded Aβ. a 6E10 DAB staining of hippocampal brain
sections 6 months after H-Aβ42/H-Aβ24 mix injection. Sagittal plane sections are shown on the left; middle and right panels show enlargements
of cerebral cortex; the injected hemisphere is referred as ipsilateral (top panel) and the non-injected one as contralateral (bottom panel). 6E10-
immunopositive aggregates are visible on a cresyl violet-luxol fast blue counterstaining. Scale bars: left 1 mm, middle 100 μm, right 50 μm. b
Quantification of 6E10 DAB positive plaques in the contralateral hemisphere 6 months after the injection of vehicle, H-Aβ42, H-Aβ24 or H-Aβ42/
H-Aβ24 mix. 6 brain sections were analyzed for each mouse (N = 3 mice for each group). Statistical analysis was performed by One way Anova,
Bonferroni multiple comparison test (**** P < 0.0001, *** P < 0.001). c Representative images of 6E10 DAB positive aggregates at the hippocampal
level 6 months after Aβ injection. Scale bar: left and middle 100 μm, right 50 μm
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matched APP/PS1 mice, both in terms of enhanced
motor activity, as indicated by the total distance traveled
(Fig. 4a), and in terms of increased anxiety levels, as re-
vealed by the longer time spent in the periphery (Fig. 4b)
and the shorter time spent in the center (Fig. 4c) of the
arena. This result was also confirmed by the sociality
task in which APP/PS1 and wt Aβ-injected mice had a
higher number of contact and spent less time with the
second animal (Fig. 4d–f ). In the NOR test, APP/PS1
mice as well as wt mice injected with the mix of the two
peptides spent less time than wt littermates exploring
the novel object at the 1 h delay test and more time ex-
ploring the novel object at the 24 h delay test, indicating
a significant defect in learning and memory (Fig. 4g and
h). Although not displaying brain aggregates, some be-
havioral alterations were detected in mice intracranially
injected with oligomeric H-Aβ42, consistent with litera-
ture data [41, 42]. Conversely, no differences were
noticed between the not injected and vehicle injected wt
mice, showing that the injection per se was not respon-
sible for the observed behavior defects. These data
indicate that injection of H-Aβ24 and, even more prom-
inently, H-Aβ42/H-Aβ24 mix into wt brain results in theoccurrence of cognitive defects comparable to APP/PS1
mice.
Predicted physico-chemical properties of Aβ24 aggregation
and cross-aggregation
We next aimed at assessing the molecular basis of aggre-
gate formation in the brains injected with H-Aβ24 or
with the H-Aβ42/H-Aβ24 mix. In order to understand
whether H-Aβ24 is endowed with different propensity to
form aggregates relative to H-Aβ42, we modeled the de-
terminants of aggregation with bioinformatics methods,
using different algorithms which predict the aggregation
propensity on the basis of sequences [26]. First, the
AMYLPRED2 consensus analysis identified two distinct
amyloidogenic regions in the full Aβ42 peptide, respect-
ively encompassing residues 15–22 and 29–42. Of the
two regions, the first was predicted in Aβ24 as well
(Table 1). This is an indication that Aβ24 maintains
fibrillogenic potential in isolation [43], although the
resulting fibrillar structure will likely be different due to
the lack of second aggregation-prone region.
Second, the PASTA 2.0 algorithm by Walsh et al. [44]
predicted the strongest self-aggregating segment in
Aβ42 to be residues 31–41 (at about−10.6 kcal/mol,
Fig. 4 Intracranial injection of H-Aβ induces behavioral defects in wt mice. a–c Mice hyperlocomotion, assessed by Open Field test. Left panel a
total distance (cm) travelled by mice in 30 min using 5 min time bin representation. b, c panels: total distance travelled in 30 min in the periphery
or in the center of the arena using 5 min time bin representation. Statistical analysis was performed by One way Anova, Bonferroni multiple comparison
test. Asterisks are referred to the vehicle vs H-Aβ42/H-Aβ24 mix condition. No significant differences are present between APP/PS1 tested mice and the H-
Aβ42/H-Aβ24 mix condition. (****P< 0.0001; ***P< 0.001; **P< 0.01). d–f Social interaction, assessed using the social free test. Graphic representation of the
number of contacts/min between the two mice in the same arena. H-Aβ42 d, H-Aβ24 e or H-Aβ42/H-Aβ24 mix f are compared to vehicle injected mice
and APP/PS1 mice. Statistical analysis was performed by One way Anova, Bonferroni multiple comparison test (**P< 0.01; *P< 0.05). g and h Assessment of
learning and memory by NOR. g Number of contacts with the new and old object either after 1 h and 24 h of delay. h Number of contacts with the new
object both after 1 h and 24 h of delay. Statistical analysis was performed by One way Anova, Bonferroni multiple comparison test. Asterisks are referred to
the control wt vs APP/PS1 mice when specified or to the vehicle vs other conditions (****P< 0.0001; **P< 0.01; *P< 0.05). A total of 33 mice
(6 mice for each experimental group plus 6 APP/PS1 and 3 wt mice 6 months old) were analysed
Table 1 Amyloigenic regions in Aβ24 and Aβ42 peptides predicted
by the 11 indicated methods, and AMYLPRED2-derived consensus
score
Method Aβ24 Aβ42
AGGRESCAN 17–22 17–22, 30–42
AmyloidMutants 4–12, 15–23 14–22, 34–42
Amyloidogenic Pattern 16–21 16–21
Average Packing Density 16–21 16–21, 32–37
Beta-strand contiguity 15–20 15–20, 29–41
Hexapeptide Conf. Energy 16–22 16–22, 29–42
NetCSSP 1–23 1–23, 28–37
Pafig 7–24 7–42
SecStr 15–20 15–20
TANGO 17–21 17–21, 29–41
WALTZ 15–24 15–23, 28–42
AMYLPRED2 (CONSENSUS5) 15–22 15–22, 29–42
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binder (by approximately 5 kcal/mol) and to have a
comparatively more marked, although still not domin-
ant, tendency towards the self-assembly in the antiparal-
lel arrangement (Fig. 5b). It is worth noting that the
algorithm also predicts cross-aggregation propensities
between segments in the 1–24 and 25–42 ranges, the
strongest pair being at−4.84 kcal/mol, which is in the
same order of magnitude of the self-aggregation propen-
sities in the 1–24 region (Fig. 5c).
Aβ24 displays a low fibrillar aggregation propensity and
supports the formation of intermolecular β-sheets
The in vitro aggregation of Aβ samples was monitored by
ThT assay [45] (Fig. 6a–c). ThT fluorescence emission was
recorded at different incubation times at 37 °C in physio-
logical buffer. Under our experimental conditions, and in
agreement with previously reported data [46], oligomeric
H-Aβ42 rapidly formed ThT-positive aggregates already
Fig. 5 Bioinformatics analysis of Aβ42, Aβ24 and cross-aggregating regions and their stabilities. Regions and energies are predicted by Walsh’s PASTA
2.0 algorithm; lower energies indicate higher fibrillation propensity. a Self-aggregation propensities for the full length Aβ42 protein; b self-aggregation
propensities for the Aβ24 fragment. c Cross-aggregation between the Aβ24 fragment and the C-terminal region (aa 25 to 42) of Aβ42
Fig. 6 In vitro aggregation of Aβ peptides studied by ThT fluorescence and infrared spectroscopy. a The time course of aggregation of Aβ42, of Aβ24, and
of the equimolar mixture of the two peptides incubated at 37 °C in PBS was monitored by ThT fluorescence with excitation and emission wavelengths at
450 nm and 485 nm, respectively. b ThT fluorescence emission spectra (excitation at 450 nm) of samples as in a) reported for selected incubation times. c
Fluorescence emission spectra with excitation at 270 nm of Aβ42 and of Aβ24 incubated at 37 °C in PBS for 96 h. d ATR-FTIR spectra of Aβ42, of Aβ24, and
H-Aβ42/H-Aβ24 mix incubated at 37 °C in PBS for different times, as indicated. Spectra are reported after Fourier self deconvolution (see Materials
and Methods)
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ThT fluorescence up to 96 h of incubation (Fig. 6a and b),
indicating a much lower fibrillation capability than H-
Aβ42. Further, we recorded the emission fluorescence
spectra of the samples incubated for 96 h at 37 °C after
tyrosine excitation at 270 nm, which is also able to
produce ThT fluorescence [47]. The tyrosine emission at
around 301 nm was detected for both H-Aβ24 and H-
Aβ42 samples, but only the latter showed the ThT emis-
sion typical of amyloid fibrils at around 485 nm (Fig. 6c).
An intermediate behavior was observed for the equimolar
mixture of oligomeric H-Aβ42/H-Aβ24 peptides (Fig. 6a
and b). The secondary structures of the peptide assemblies
were also investigated by Fourier transform infrared
(FTIR) spectroscopy in attenuated total reflection (ATR)
[48, 49] (Fig. 6d). The FTIR spectra of the H-Aβ24 sam-
ples incubated at 37 °C for 20 min and for 6 days were
characterized by a broad Amide I band, due to the C =O
stretching vibrations of the peptide bond, with two main
peaks at ~1695 cm−1 and ~1628 cm−1, assigned to the for-
mation of intermolecular β-sheet structures. In compari-
son to H-Aβ24, H-Aβ42 at 20 min displayed a higher
intensity of the ~1628 cm−1 peak. During incubation at
37 °C of H-Aβ42, this component increased in intensity
while that at ~1695 cm−1 decreased (Fig. 6d). These spec-
tral changes have been already observed in the fibrillogen-
esis of Aβ peptides and of other proteins, and assigned to
the conformational conversion towards fibrillar structures
with a parallel orientation of the intermolecular β-sheets
[48, 49]. An intermediate behavior was observed for the
equimolar H-Aβ42/H-Aβ24 mix (Fig. 6d). Therefore, the
spectroscopic analyses indicated a low fibrillization pro-
pensity for H-Aβ24 and confirmed the higher antiparallel
content of this peptide, as predicted by bioinformatics
analysis (Fig. 5c). These data, together with the cross-
aggregation potential between H-Aβ1-24 and H-Aβ25-42
(Fig. 5c), suggest that H-Aβ24 may promote aggregate for-
mation involving intermolecular β-sheet interactions,
which possibly retain H-Aβ42 through cross-aggregation
between segments in the 1–24 and 25–42 ranges.
Synthetic Aβ24 fragment impairs Aβ42 clearance in a
blood brain barrier model
To directly investigate whether oligomeric H-Aβ24 forms
aggregates retaining Aβ42 and impairing the clearance of
Aβ42 through the blood brain barrier (BBB), we used an
in vitro BBB transwell model, formed by (brain) endothe-
lial bEnd.3 cells cultivated in the abluminal compartment
of cell culture inserts until a post-confluent monolayer
had grown (Fig. 7a). Confirmation of the morphological
and functional properties of the endothelial cell monolayer
(Fig. 7b) were obtained by immunostaining for the tight
junction proteins claudin5 (Fig. 7c) and ZO1 (Fig. 7d),
connexin43 (CX43) (Fig. 7e) and by the transendothelialelectrical resistance (TEER) values reached from day 7
after plating (Fig. 7f). The in vitro BBB model was used to
investigate the passage of FAM-labeled or 488-conjugated
H-Aβ42 across the endothelial cell monolayer. While the
addition of fluorescently labeled H-Aβ42 to the apical side
of cell inserts resulted in effective BBB crossing, fluores-
cently labeled scrambled H-Aβ42 was not efficiently trans-
cytosed (Fig. 7g) thus confirming the reliability and the
selectivity of the model as described in literature [50].
Notably, the concomitant presence of H-Aβ24 at the
apical side of the cells significantly reduced fluorescently-
labeled H-Aβ42 transfer (Fig. 7g, h). No effect of H-Aβ24
on the diffusion of fluorescently labeled scrambled H-
Aβ42 was detected (Fig. 7g, h). Similar results were ob-
tained using different Aβ42 concentrations (1 μM or 100
nM Aβ42, Fig. 7g and h). Consistently, H-Aβ42 apical-to-
basolateral passage, detected by dot blot analysis of
medium recovered from the basolateral compartment, re-
vealed a decreased amount of H-Aβ42 when the latter was
pre-incubated with H-Aβ24 at the apical side (Fig. 7i).
These data indicate that H-Aβ24 presence results in H-
Aβ42 retention, thus reducing its efflux through the BBB
and therefore preventing an efficient mechanism of Aβ42
clearance.
Given that H-Aβ24 retains H-Aβ42, thus reducing its
clearance through the BBB, lower H-Aβ42 levels in the
circulation are expected. For this reason, H-Aβ42 levels
were quantified by ELISA assay in serum samples of wt
mice 1 week after injection of amyloid species into the
brain. As expected, increased Aβ42 peripheral levels
were detected in Aβ42 i.c. injected mice (Fig. 7j). Not-
ably, a significant reduction of H-Aβ42 peripheral levels
was detected when H-Aβ24 and H-Aβ42 were injected
together into the brain at equimolar amounts (4pmol of
H-Aβ42 or 2pmol of H-Aβ24 plus 2pmol of H-Aβ42)
(Fig 7k). In order to exclude that the lower Aβ42 plasma
content, observed after the i.c. injection of H-Aβ24 and
H-Aβ42, could result from the reduced amount of Aβ42
injected (2pmol vs 4 pmol), the experiment was repeated
upon injection of the same amount of Aβ42, either in as-
sociation or not with Aβ24 (8pmol of H-Aβ42 or 8pmol
of H-Aβ24 plus 8pmol of H-Aβ42). Reduced Aβ42 per-
ipheral levels were detected also in this case when H-
Aβ24 was co-injected together with H-Aβ42 (Fig. 7l).
Injected H-Aβ24 aggregates with endogenously produced
mouse Aβ42
Considering that H-Aβ24 would reduce Aβ42 clearance
thus causing an increase in the levels of brain Aβ42, we
hypothesized that deposits observed in mice injected
with only H-Aβ24 could derive from a co-aggregation of
the injected peptide and endogenously produced mouse
Aβ42, retained in the brain. Consistently, immunoblot
analysis of brain homogenate fractions using Aβ-specific
Fig. 7 Aβ24 fragment diminishes Aβ42 clearance through the BBB. a Graphical representation of the in vitro BBB model composed by a monolayer of
brain endothelial cells seeded and cultured on an inverted matrix-coated porous membrane, allowing an apical compartment (donor-“brain”-side)
physically separated from the basolateral chamber (receiving-“blood”-side). b Representative images of brain endothelial cells tightly wedged together and
c expressing cell type-specific tight junctional proteins claudin-5 (green) d and ZO-1 (green), and e the gap junction protein Connexin-43 (green). Nuclei
counter-stained with DAPI (blue). Scale bars: 20 μm. f Barrier properties monitored in terms of gradual increase in transendothelial electrical resistance (TEER)
during cell monolayer’s formation over time. g and h Apical-to-basolateral exchange across endothelial monolayer of fluorescent Aβ42 or scramble Aβ42
control peptide, 1 μM g) or 100 nM h), over 120 min in presence or absence of Aβ24 at equimolar concentration. Quantification of unidirectional trans-
endothelial Aβ42 transport by fluorescence spectrophotometry n≥ 3 experiments; statistical analysis was performed by One way Anova, followed by
Bonferroni’s post hoc test for multiple comparisons (**P< 0.01; ***P< 0.001). i) Dot blot analysis of medium collected in the abluminal compartment
120 min after brain endothelial cell monolayers exposure to Aβ42 or Aβ42/Aβ24 mix. Histograms represent the densitometry quantification upon staining
with anti-6E10 antibody. Results are expressed as mean values of triplicates in each experimental group ± SE. Values were normalized on control; statistical
analysis was performed by unpaired T test (**P< 0.01). j Aβ42 (pg/ml) absolute values detected by ELISA in the serum of mice 1 week after H-Aβ42
intracranical injection. k Aβ42 serum level measured 1 week after the injection of vehicle, H-Aβ42 and H-Aβ42/H-Aβ24 mix (2pmol of H-Aβ24 plus 2pmol
of H-Aβ42) or l H-Aβ42/H-Aβ24 mix (8pmol of H-Aβ24 plus 8pmol of H-Aβ42). N= 4 to 6 animals per experimental group. Values are normalized on
vehicle. Statistical analysis was performed by unpaired T test (*P< 0.05)
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15 of murine Aβ [51] (Fig. 8; supernatant, top panel and
pellet, bottom panel) showed the presence of m3.2 positive
bands (squares) in wt mice injected with H-Aβ24 and, at a
lesser extent in mice injected with H-Aβ24/H-Aβ42 mix.
This result corroborates our hypothesis by which H-Aβ24
injected in the brain interacts with endogenously produced
mouse Aβ42. As a specificity control, brain homogenates of
mice lacking the amyloid precursor protein APP (App−/−)
were negative for the m3.2 antibody (Fig. 8).
Microglial MMP9 is responsible for Aβ42 degradation and
for the production of a C-terminal truncated Aβ fragment
In AD patients and in transgenic models of the disease,
microglial activation in response to Aβ is followed by Aβ
internalization via phagocytosis, in an attempt of restoringhomeostatic conditions [52–55]. However, on the other
hand, microglia might be detrimental exacerbating Aβ
deposition and causing neuronal damage through the
production of amyloidogenic, truncated forms of Aβ
[12, 54]. To obtain the proof-of-concept that C-
terminal truncated fragments could be produced by
microglia, we treated primary microglia cultures with
488-conjugated H-Aβ42 and in line with literature, we
observed that already after 3 h of treatment Aβ was
efficiently internalized by the cells (Fig. 9a). We took
advantage of different antibodies, which recognize dis-
tinct portions of the protein to assess the formation of
H-Aβ42-derived Aβ forms (Fig. 9b). Double immuno-
fluorescence using antibodies against the C-terminal
(anti-Aβ42) and the N-terminal (6E10) regions of Aβ42
revealed that, 24 h after its internalization, an antigen
Fig. 8 Production of murine-Aβ in H-Aβ24 and H-Aβ24/H-Aβ42 injected
mice. Tris-Tricine SDS–polyacrylamide gel electrophoresis (PAGE) followed
by immunoblotting using murine-Aβ-specific monoclonal antibody m3.2
of brain homogenate factions (supernatant, top panel and pellet, bottom
panel) of mice injected with vehicle, H-Aβ24, H-Aβ42 or H-Aβ24/H-Aβ42
mix and analyzed after 4 months. Asterisks indicate the presence of 6KDa
band positive to m3.2 antibody only in the pellet fraction of mice injected
with H-Aβ24. Actin was used as loading control
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ively recognized by the 6E10 (N-ter) but not by the
anti-Aβ42 (C-ter) (Fig. 9b arrows).
In line with the formation of a truncated Aβ42 form,
dot blot analysis of the extracellular medium of micro-
glia exposed to H-Aβ42 revealed, after 24 h, a reduction
of extracellular Aβ42, when stained by the C-terminal
anti-Aβ42 (directed against the aa 38–42) but not by the
6E10 antibody, directed against the N-terminal domain
of Aβ42 (aa 1–16) (Fig. 9c). We then quantified Aβ42
extracellular concentrations over time using an Aβ42
ELISA kit based on a capture antibody directed against
the C-terminal domain of the protein and a detection
antibody against aa 11–28. Consistently, we observed a
significant decrease of Aβ42 in the microglia medium,
starting from 12 h after treatment (Fig 9d, left). On the
contrary, an ELISA kit based on the capture antibody
6E10 revealed the lack of changes in the amount of
Aβ42 in the medium of microglia (detection antibody
4G8 against the central part of Aβ42, aa 17–24, Fig. 9d,right). Notably, ELISA for the C-terminal domain of the
protein revealed that the modifications in the nature of
the extracellular amyloid fragments were prevented by
microglia incubation with protease inhibitors (Fig. 9e),
indicating that microglia promote the metabolic process-
ing of Aβ42, thus favoring the production of fragments
which include the N-terminal, but not the C-terminal
domain of the Aβ peptide. The lack of changes in the
amount of Aβ42 in the medium of microglia, as detected
with the antibody 4G8 which recognizes aa 17–24
(Fig. 9d), suggests that the truncated fragment contains
the N-terminal part of the protein up to at least aa 23–
24, residues which are known to be cleaved by MMP9
[20]. Consistently with the involvement of MMP9 in
Aβ42 processing, the production of the C-terminal trun-
cated fragment was inhibited in microglia cells lines
(N9) exposed to specific MMP9 siRNA to reduce the en-
zyme expression (Fig. 9f ). The same results were ob-
tained by dot blot staining. Indeed, the exposure of
primary microglia to protease inhibitors (Fig. 9g and h),
the knocking-down of MMP9 in N9 cells (Fig. 9g and i)
as well as the use of primary microglia from MMP9 −/−
mice (Fig. 9g and j) prevented the reduction in the
amount of the C-terminal fragment in the medium of
cells exposed to Aβ42 for 24 h. Staining with 6E10 anti-
body revealed the same amount of N-terminal fragments
in the extracellular media of cells under the different ex-
perimental conditions (Fig 9g, right). To demonstrate
that the N-terminal fragments deriving from microglia
proteolytic activity are responsible for a diminished
Aβ42 clearance in vitro, we performed the same experi-
ment as in Fig. 7g, by incubating the BBB model with
microglia conditioned medium (previously treated with
unlabeled Aβ42 for 24 h) in the presence or absence of
protease inhibitors. As expected, adding microglia condi-
tioned medium significantly reduced 488-conjugated H-
Aβ42 clearance across brain endothelial cell monolayers.
The presence of protease inhibitors in microglia medium
increased fluorescently labelled H-Aβ42 passage through
the BBB (Fig. 9k). Overall, these results suggest that
microglia play a central role in the production of C-
terminal truncated fragments by the activity of extracel-
lular proteases. This phenomenon could be responsible
for an enhanced Aβ42 deposition and seeding in the
healthy brain.
Discussion and conclusions
Although the significance of amyloid deposits for the
pathogenesis of AD is still under debate [56–58], the obser-
vation that, in brain, harmful proteins show high propensity
to aggregate indicates that formation of deposits is import-
ant in the pathogenesis of brain disorders. While Aβ-
containing brain extracts from AD patient or transgenic










































































































































































































































Fig. 9 Microglia promote the formation of a C-terminal lacking amyloid fragment in vitro. a 3D reconstruction by Imaris software of microglia cells
(Iba1 positive, red) treated or not for 3 h with 1 μM Aβ42–488 (green). Scale bar: 4 μm. b Bright field images of microglia cells stained with 6E10
(red) or anti-Aβ42 (green) antibodies, before (left panel) or after (right panel) 24 h incubation with H-Aβ42. Arrows indicate 6E10 positive puncta
not co-localizing with anti-Aβ42 positive domains. Scale bar: 10 μm. On top: schematic representation of H-Aβ42 sequence, showing the binding sites for
the different antibodies. c Dot blot analysis of the extracellular medium collected 6 and 24 h after microglia exposure to H-Aβ42. Histograms represent the
densitometry quantification upon staining with anti-Aβ42 C-terminal antibody (left histogram) or 6E10 N-terminal antibody (right histogram). Intensity
values are shown. N= 5 independent experiments, statistical analysis was performed by One way Anova, Bonferroni multiple comparison test (**P< 0.01,
*P< 0.05). d Quantification of Aβ42 extracellular levels in microglia cultures exposed to H-Aβ42 for the indicated time points. Two different ELISA kits based
on a capture antibody against the C-terminal (left) or N-terminal (right) domains of the protein were used. N= 5 independent experiments. Statistical
analysis was performed by One way Anova, Bonferroni’s post hoc test for multiple comparisons (*** P< 0.001). e ELISA of C-terminal-containing Aβ42 in
the extracellular medium of microglia exposed to H-Aβ42 in both control conditions and in the presence of protease inhibitors. N= 3 independent
experiments. Statistical analysis was performed by two way Anova, Bonferroni’s post hoc test for multiple comparisons. f ELISA of C-terminal-containing
Aβ42 in the extracellular medium of N9 cells exposed to siRNAcontrol or MMP9siRNA. Statistical analysis was performed by two way Anova, Bonferroni’s
post hoc test for multiple comparisons. g Representative dot blots of the extracellular medium from H-Aβ42-treated microglia in control conditions, in the
presence of protease inhibitors, from siRNAcontrol or MMP9siRNA or from MMP9−/− microglia. Blots are immunostained with anti-Aβ42 or 6E10 antibodies.
h-j Dot blot quantification of the extracellular medium collected from microglia in control conditions or in the presence of protease inhibitors h), from
siRNAcontrol or MMP9siRNA i) or from MMP9−/− microglia j) after 6 and 24 h of Aβ42 treatment. k) Apical-to-basolateral exchange across the BBB of
fluorescent Aβ42 over 120 min upon pre-incubation with Aβ42-treated microglia conditioned medium in the presence or absence of protease inhibitors.
Quantification of unidirectional trans-endothelial Aβ42 transport by fluorescence spectrophotometry of N= 2 independent experiments; statistical analysis
was performed by One way Anova, Bonferroni’s post hoc test for multiple comparisons (**P< 0.01)
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dicate that intracranial injection of a single form of syn-
thetic Aβ (Aβ42) does not induce plaque formation in wtbrain. Here we show that the injection of a C-terminal
truncated synthetic Aβ peptide (Aβ24), which may result
from microglial MMP9 proteolytic activity, has seeding
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wild type mice. Our results thus provide a direct demon-
stration of the concept that biologically relevant mixtures
of Aβ forms may result in vivo in more complex aggrega-
tion dynamics than those predicted by in vitro studies. Not-
ably, amyloid deposits are sporadically detectable also in
the non-injected hemisphere and in the hippocampus, thus
excluding they may represent post-injectional sprouting or
leftover after cortical injection and brain lesioning.
Although it is known that the number of amyloid plaques
does not necessarily correlate with cognitive impairments
([60–62]; reviewed in [63]), the presence of amyloid de-
posits at the hippocampal level may explain the occurrence
of the behavioral defects observed in injected in healthy
mice.
It is now established that protein aggregation takes
place, biophysically, once a critical concentration of
proteins has been overcome [64]. The lag phase is re-
duced by the presence of “seeds” [64], which enhance
fibrils formation. An efficient process of clearance is re-
quired in order to prevent the increase in concentration
of “seeds”, which may in turn initiate the aggregation
process [64]. Consistently, Aβ clearance rates were
found to be impaired in AD patients compared to cog-
nitively normal controls, while there were no differ-
ences in Aβ production rates [65]. Although no specific
evidence on the clearance of oligomeric forms is cur-
rently available, oligomeric Aβ intermediates have been
found to alter proteasomal clearance [66].
Several mechanisms for Aβ clearance have been iden-
tified, including drainage via the BBB, which is mostly
mediated by the low-density lipoprotein receptor related
protein-1 (LRP1). LRP1 is localized on the abluminal
side of the brain capillary endothelium and mediates Aβ
transport across the BBB in the direction of brain to
blood [67–69]. When Aβ binds to LRP1 at the brain side
of the BBB, a process of transcytosis starts, which medi-
ates rapid Aβ clearance. Notably, LRP1 expression is re-
duced during aging and in AD as well as in patients with
the Dutch-type of cerebrovascular β-amyloidosis. The
transcytosis process is very efficient and, indeed, human Aβ
injected into different brain regions of wt mice is rapidly re-
covered in the plasma [70]. Consistently, no plaques nor ag-
gregates are formed in wt brain upon injection of Aβ42 [8,
9]. Interestingly, post-translationally modified forms of Aβ
are cleared less efficiently from the brain, like in the case of
N-terminal truncated and pyroglutamate-modified Aβ and
phosphorylated Aβ [71, 72]. Notably, Aβ peptides with
higher β-sheet content are cleared less efficiently from
brain, due to a low-affinity LRP/Aβ interaction, mediating
brain accumulation of amyloid. Based on the view that in-
sufficient clearance of Aβ plays an essential role in the
pathogenesis of AD [73], one may speculate that even low
amounts of Aβ forms impairing physiological Aβ clearanceand, thereby, increasing Aβ concentration, may foster dis-
ease progression [64].
We demonstrate that Aβ24, when concomitantly
present with Aβ42 at the abluminal side of the endothe-
lium, slows amyloid clearance through BBB. This is
likely due to the fact that H-Aβ24 aggregates, which dis-
play higher antiparallel character, retain Aβ42, thus
impairing its clearance through the BBB. Although we
cannot exclude that Aβ42 levels measured in the serum
of injected mice may reflect other routes of clearance
besides BBB, our results suggest that the same mechan-
ism may operate also in vivo. In particular, impaired
clearance might overcome the critical concentration of
proteins initiating the aggregation process and causing
the formation of ThT, Congo-red and 6E10-positive
aggregates detected in wt brains upon injection of the
H-Aβ24/H-Aβ42 mix. Hence, H-Aβ24, and possibly
other C-terminal truncated fragments, may function as
scaffold proteins to favor both human (in the case of H-
Aβ24/H-Aβ42 mix injection) and mouse Aβ42 (in the
case of H-Aβ24 injection) recruitment, fibrillation and
deposition. Interestingly, Aβ24 has been detected as a
major amyloid component in leptomeninges of patients
affected by HCHWA-D (hereditary cerebral hemorrhage
with amyloidosis, Dutch type). These data indicate that
the Aβ24 fragment is in fact formed also in human
brain, possibly generated by carboxyl-terminal limited
proteolysis [74]. Although future studies will be required
to clarify what type of Aβ is deposited, our results are in
line with the work of Schlenzig and colleagues which
showed that N-terminally truncated and pyroglutamate-
modified amyloid beta peptides are less soluble than full-
length peptides, increasing aggregation propensity and
seeding of amyloid peptides [64, 75]. Notably, wt mice
injected with H-Aβ24 alone or with H-Aβ24/H-Aβ42 mix,
display, besides Aβ protein deposition, behavioral defects
similar to those of age matched APP/PS1 mice.
One may want to consider whether structural informa-
tion available for Aβ peptides could provide a possible
rationalization of the effect of cleavage at residue 24.
The structural arrangement of Aβ fibrils and, even more
importantly, oligomers and intermediates is still a matter
of debate; structural determinations are made difficult,
among other factors, by the presence of extensive poly-
morphisms [76]. For fibrillar aggregates, numerous stud-
ies point towards a β-sandwich motif, i.e. two sheets
with strands oriented perpendicular to the long axis of
the fibril; β-sandwiches are in turn arranged in higher
order structures, i.e. with two-fold or three-fold sym-
metry around the fibril axis [77]. A common feature of
such models is that the two sheets comprise the two
separate aggregation-prone regions identified above;
therefore, the elimination of the C-terminal region in
Aβ24 would delete one of the sheets, and hence be
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rangement (Fig. 10).
Although the consensus is weaker for what concerns
the structure of oligomeric aggregates and other pos-
sible kinetic intermediates, recently proposed models
on the basis of NMR data [78] again foresee the pres-
ence of cross-β contacts between the two extended
amyloidogenic regions identified above. Based on our
results and the fact that fibrillar and oligomeric aggrega-
tion coexist in a “competitive equilibrium”, one may
hypothesize that the presence of Aβ24 shifts the competi-
tive balance towards oligomerization, and away from fib-
rillation. Structurally, this is consistent with the following
data: first, although there is no conclusive structure for
Aβ42, NMR-derived models (Fig. 10) have a consensus in
attributing the steric zipper (the dry spine of a parallel-β
fibril) to the 25–42 C-terminal region of Aβ42, which is of
course absent in Aβ24; second, the two algorithms provid-
ing a prediction for the parallel/antiparallel character of fi-
brils (Walsh’s and Tartaglia’s) indicated that Aβ24 still has
aggregation potential, a relatively larger antiparallel β
propensity and that there is cross-aggregation potential
between Aβ1-24 and Aβ25-42. Finally, the 16–21 KLVFFA




Fig. 10 Two-fold a and three-fold b symmetric structural models reported
Peptide residues 9 to 24 shown in solid orange; residues 25 to 40 are trans
KLVFFA region highlighted; KLVFFA has been crystallized by Eisenberg et aKLVFFA has been crystallized by Eisenberg and collab-
orators in the antiparallel configuration [79]. These
data are consistent with previous observations that the
Aβ24 fragment is present in both monomeric and ag-
gregated forms [55].
Aβ24 represents a prototypical example of a C-
terminal truncated fragment generated by Aβ42 prote-
olysis. Indeed, in line with the concept that Aβ42 is in-
ternalized and metabolized by microglial cells [80–82],
we provide the evidence that C-terminal truncated frag-
ments can be produced by microglia in a protease-
dependent manner. These fragments may share similar
properties to those of Aβ24. Among those produced by
MMP9 (1–16, 1–20, 1–23, 1–30, 1–33 and 1–34, [19]),
one could argue that only Aβ16 should have a different
character than the other fragments, because it lacks the
16–20 region which is known to be amyloidogenic and
predicted as such by Walsh’s algorithm (among others)
for all other proteolytic products. One would therefore
argue that, in the 1–16 case, both hypothetical self-
aggregation and cross-aggregation pathways would be
abolished (Fig. 10). Conversely, C-terminal truncated
fragments from the cleavage site at aa residue 20 up to




for Aβ40 by Tycko et al. [94]; and c the NMR model by Ishii et al. [89].
parent; residues 1–8 were not resolved. d same as c), with the 16–21
l. in the antiparallel configuration [79]
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possibly exceeding the aa 34 is more questionable, given
that fragments produced by microglia lack the C-terminal
region, as recognized by the antibody against aa 34–42.
The role of microglia in the production of fragments
which could in principle favor plaque formation, like
Aβ24, adds an additional detrimental role to microglia
in AD. Indeed, an inverse correlation exists between
microglia activation and neurodegeneration [83] or cog-
nitive impairment [81, 84], indicating the occurrence of
a vicious cycle based on Aβ deposition, inflammation,
neuronal damage and cognitive decline. Our evidence
demonstrates that microglia may produce, through their
metabolic activity, C-terminal truncated Aβ forms which
in turn could initiate amyloid aggregation and cause
phenotypic defects even in the absence of genetic muta-
tions associated with AD. Here we provide new evidence
for the contribution of microglia activation to the devel-
opment of the sporadic form of AD.
Materials and methods
Mice
Mice were housed in the SPF animal facility of Humani-
tas Clinical and Research Center in individually venti-
lated cages. Procedures involving animals handling and
care conformed to protocols approved by the Humanitas
Clinical and Research Center (Rozzano, Milan, Italy) in
compliance with national (4D.L. N.116, G.U., suppl. 40,
18-2-1992) and international law and policies (EEC
Council Directive 2010/63/EU, OJ L 276/33, 22-09-2010;
National Institutes of Health Guide for the Care and Use
of Laboratory Animals, US National Research Council,
2011). The study was approved by the Italian Ministry of
Health (approval n. 6/2014). All the experimental proce-
dures followed the guidelines established by the Italian
Council on Animal Care and were approved by the Ital-
ian Government decree No. 27/2010. All efforts were
made to minimize the number of subjects used and their
suffering. Mice were housed in cages with free access to
food and water at 22 °C and with a 12-h alternating
light/dark cycle. Double transgenic APPswe/PSEN1dE9
(APP/PS1) mice were purchased from Jackson Labora-
tory [85]. C57BL/6 J-App (App−/−) mice were provided
by Hertie Institute and Deutsches Zentrum für Neurode-
generative Erkrankungen (DZNE), Tübingen, Germany.
BALB/c Mmp9 < tm1Tvu > (MMP9−/−) P1-P3 pups were
provided by Istituto Nazionale dei Tumori, Milan, Italy.
Preparation of synthetic Aβ peptides
Synthetic human Aβ1–42 and Aβ1–24 were purchased
from Bachem and prepared as previously described [86]
to obtain oligomeric Aβ forms. Briefly, lyophilized Aβ
1–42 and 1–24 were dissolved in dimethyl sulfoxide
(DMSO, Sigma) to a concentration of 2 mM and storedin small aliquots at−80 °C. Immediately prior to use, ali-
quots were quickly resuspended in 50 mM NaPi,
100 mM NaCl pH 7.4 buffer at a concentration of
40 μM, strongly vortexed, sonicated for 30 s and left at
room temperature for 20 min before being further di-
luted for in vivo and in vitro experiments (the concen-
tration used for each experiment is specified in the
figure legend). For Aβ clearance experiments, Aβ42–488
(HILyte, AnaspeC) and Aβ42-FAM (Anaspect) were
solubilised in NH4OH and stored in small aliquots at
−80 °C.
Antibodies
Antibodies used for immunoblot (western/dot blot), immu-
noprecipitation, and immunofluorescence were as follows:
monoclonal antibody 6E10 (1:2000; Covance), which recog-
nizes residues 1–16 of human Aβ; rabbit anti-human beta
amyloid 1–42 (1:1000; Alpha Diagnostic International)
which recognizes C-terminal 6 aa peptide from human beta
1–42; 4G8 antibody (1:2000; Covance) directed against the
central part of Aβ42 (aa 17–24); m3.2 (kindly provided by
Prof. Paul Matthews) recognizes residues 10–15 of murine
Aβ; rabbit anti-Iba1 antibody (1:500; Wako); ZO-1 (1:1000,
clone R40.76, Millipore); Connexin-43 (1:400; C6219,
Sigma); Claudin-5 (1:800; ABT45, Millipore). Secondary
antibodies (1:200; Alexa Fluor®-conjugated, Molecular
Probes).
Prediction of aggregation propensities
We used the AMYLPRED2 meta-predictor [87] to com-
pare the aggregation profiles of the sequences of full
Aβ42 peptide with respect to the truncated form includ-
ing Aβ residues 1–24 (henceforth Aβ24). The meta-
predictor identifies putative amyloigenic regions on the
basis of the consensus between 11 methods considering
a range of physico-chemical properties. Further analysis
was carried out with the algorithms PASTA 2.0 [44] and
PAGE/ABSOLUTERATE [88] in order to obtain quanti-
tative predictions of putative aggregation propensities,
rates, and the fibrillar’s beta-strand parallel versus anti-
parallel character. Putative three-dimensional fibrillar
arrangements were obtained from the PDB database en-
tries 2LMN, 2LMP, 2MXU [89].
Thioflavin T (ThT) assays
Thioflavin T (ThT) dye was purchased from Sigma
Aldrich. For the ThT assays, 200 μL of Aβ42 (at 8 μM
concentration), of Aβ24 (at 8 μM concentration), or of
the equimolar mixture of the two peptides (at 4 μM con-
centration each) were incubated in 50 mM NaPi,
100 mM NaCl pH 7.4 buffer at 37 °C with ThT at 10 μM
concentration. At different incubation times, the fluores-
cence emission spectra of the samples were collected
after excitation at 450 nm [45] or at 270 nm [47] by the
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Ltd, Mulgrave VIC, Australia). Quartz cuvettes of 1 cm
path length were employed. For time course experi-
ments, the samples were kept at 37 °C and analyzed at
each time point.
ATR-FTIR spectroscopy
For the ATR-FTIR measurements, 2 μL of Aβ42 (at
100 μM concentration), of Aβ24 (at 100 μM concentra-
tion), or of the equimolar mixture of the two peptides
(at 50 μM concentration each) were deposed on the sin-
gle reflection diamond element of the ATR device
(Quest, Specac, UK). Spectra were recorded after solvent
evaporation to allow the formation of an hydrated film
as previously described [48]. FTIR measurements were
performed using the Varian 670-IR spectrometer (Varian
Australia Pty Ltd, Mulgrave VIC, Australia) under the
following conditions: 1000 scan coadditions, 25 kHz of
scan speed, 2 cm−1 of spectral resolution, triangular
apodization, and a nitrogen-cooled Mercury Cadmium
Telluride detector. Fourier self deconvolution was ob-
tained with a full width at half height of 13.33 cm−1 and
a resolution enhancement factor K = 1.5 [48] using the
Resolutions-Pro software (Varian Australia Pty Ltd, Mul-
grave VIC, Australia).
Intracranial injections
Stereotaxic intracranial injections in mice brains were
made under a mixture of ketamine (100 mg/kg) and
xylazine (10 mg/kg) anesthesia. After surgical exposure
of dura mater, both the bregma and the skull surface
served as the stereotaxic zero points. Using a Hamilton
syringe, 4 μL of H-Aβ or vehicle (vehicle consists of
physiological buffer−50 mM NaPi, 100 mM NaCl
pH 7.4−) were injected into the neocortex (AP 1 mm,
ML 2 mm, DV−2 mm) with a speed of 1.5 μL/min, the
needle was kept in place for an additional minute be-
fore it was slowly drawn out. For each experiment 4
pmol of H-Aβ42, 4 pmol of H-Aβ24 and 2 pmol of H-
Aβ42 plus 2 pmol of H-Aβ24 for the mix condition
were injected, as described in [70, 90]. Different condi-
tions were used for specific experiments as specified in
the text. After suturing the incision, mice were
maintained on a warm pad until recovery from the
anesthesia, then returned to their cages. All procedures
were conducted in accordance with institutional guide-
lines for the care and use of experimental animals.
Behavioral tests
Open field
Mice were placed in a multi-unit open field maze (View-
Point instruments) with field chamber (25 cm long and
25 cm wide), and activity was recorded using ViewPoint
video tracking software. Each quadrant was digitallydivided into a peripheral and a central region using
ViewPoint video tracking software. The central quad-
rants are collectively referred to as the center zone and
peripheral quadrants are collectively referred to as the
peripheral zone. Data were collected continually for
30 min and the distance traveled (cm), velocity (cm/s),
and the distance traveled in the center zone versus the
peripheral zone were all recorded and scored automatic-
ally. In the open field task ambulatory movements (val-
ued as distance traveled and movement speeds) and
anxiety-like behaviors (as the as distance traveled in the
center zone versus the peripheral zone) can be assessed
in response to a novel environment.Social interaction task
The social interaction test was used to measure how mice
respond to a social partner during a 5-min test following
isolation housing. Since isolation housing potentiates ex-
pression of innate territorial defensive responses, in this
test we evaluated the reaction of mice to the presence of a
new animal in free conditions in the same arena. For this
test, mice were placed for 30 min alone into the open field
arena to familiarize themselves with the new environment.
After this time a new female was introduced and the rec-
ord started. We used the ViewPoint system to count the
number of time the tested mouse made contact with the
new females. The decision to use females was made to
avoid any occurring of an aggressive behaviour simply
caused by a normal intermale instinct.Novel object recognition (NOR)
The test apparatus consisted of an open field box measur-
ing 50 cm × 25 cm and all sessions were video-recorded.
The first day the animal was allowed to explore the empty
field arena for a 10-min time period (habituation session)
before being exposed to a 10-min period of familiarization
session in the presence of identical objects (A/A). This
familiarization session was followed by 1 h and 24 h delays
during which the animals were returned to their home
cages. After the delay the animals performed 10-min of test
session (A/B) in which one object was kept as during the
familiarization session (A) and another was changed (B).
The objects were made of hard plastic and had previously
been counterbalanced to control for any object preference
bias. The total amount of time spent with each object was
recorded and scored using fully automated ViewPoint video
tracking software. The time spent around each object was
defined as the time in which the animal directed its nose to
the object at a distance <2.0 cm and/or by the animal
touching the object with its nose. Data are shown as the
total amount of time that animals spend exploring the
novel object during both the 1 and 24 h delay.
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Primary microglia were obtained from mixed cultures pre-
pared from the cerebral cortex of mice at the postnatal
day 1 (P1-3). Microglia cells were isolated by shaking
flasks for 45 min at 230 rpm at day 10 after plating. Cells
were then seeded on poly-L-ornithine (Sigma) pre-coated
wells at the density of 1,5×105 cell/mL in DMEM contain-
ing 20 % heat-inactivated fetal bovine serum (FBS) and in-
cubated at 37 ° C in a humidified atmosphere of 5 % CO2
and 95 % air. Where indicated, cells were pre-treated for
45 min with protease inhibitors and EDTA 2.5 mM
(Roche) which were directly added to the cell culture
medium. N9 cells were maintained in IDMEM (Gibco
Laboratories, USA), supplemented with 10 % FBS. For
siRNA transfection, N9 cells were plated at a concentra-
tion of at 1×105 cells/mL into either 96 or 24 multiwell
plate. Specific siRNAs were diluted at a final concentra-
tion of 20 nM siRNA. Cells were used within 48–72 h
after transfection. When not differently indicated, for
in vitro experiments microglia were treated with H-Aβ42
400 nM.
Endothelial cells culture and BBB model
Mouse brain endothelial cells (bEnd.3) [BEND3] (ATCC®
CRL2299™) were used as a representative BBB model.
bEnd.3 cells were cultured at 37 °C, 5 % CO2/saturated
humidity in DMEM supplemented with 10 % heat-
inactivated fetal bovine serum (FBS), 1 % penicillin-
streptomycin.
Transendothelial cell electrical resistance (TEER) assay
bEnd.3 cells were seeded at a concentration of 30000
cells/cm2 onto geltrex-coated (thin layer; Gibco) trans-
well inserts (polycarbonate, 12 mm diameter, 3 μm pore
size; Costar) until a monolayer was established. TEER
was assessed using a Voltohmeter (Millicell Electrical
Resistance System, Millipore). Background resistance
from cell-free matrix-coated transwells was subtracted
from recorded values to determine absolute TEER values
and corrected for the area covered by the cell mono-
layer. TEER was measured once a day to monitor cell
confluence and development of tight junctions. Change
in absolute TEER from T0 for each individual transwell
was recorded over time and then averaged for each day
before treatment.
Aβ42 permeability of the endothelial barrier
To assess Aβ42 exchange across the BBB model, bEnd.3
cells were cultured upside-down on a transwells system as
described above, until steady-state TEER had been
reached. 1 μM FAM-labeled Human Beta-Amyloid (1–42)
or FAM-labeled scrambled Beta-Amyloid (1–42) or
HiLyte Fluor™ 488-labeled Beta-Amyloid (1–42) (Anaspec
Peptide, Eurogentec) in the presence or absence ofHuman Beta-Amyloid (1–24) (Bachem) were pre-
incubated for 20 min in FluoroBrite™ DMEM (Gibco)
medium at 37 °C, and added to the apical (brain) side cor-
responding to the donor compartment. The basolateral
(blood) side of the transwells represented the receiver side
and was exposed to medium alone. Alternatively, primary
microglial cells were incubated for 24 h at 37 °C in Fluoro-
Brite™ DMEM medium containing Human Beta-Amyloid
(1–42) (Bachem) in the presence or absence of protease
inhibitors (Roche). Microglia conditioned medium was
recovered and spun for 2 min at max speed. 1 μM HiLyte
FluorTM 488-labeled Beta-Amyloid (1–42) was pre-
incubated for 30 min at 37 °C with microglia conditioned
medium, and added to the apical compartment. Following
120 min of incubation at 37 °C with slow mixing, samples
were collected from the upper and lower chambers to as-
sess the movement of fluorescently-labelled Aβ42 across
the bEnd.3 monolayer (apical to basolateral). The level of
fluorescence in the media collected was measured for
488-Aβ42 (λex = 503 nm and λem = 528 nm) or for FAM-
Aβ42 (λex = 492 nm and λem = 518 nm) using a Synergy™
H4 Hybrid Multi-Mode Microplate Reader (BioTek). Rela-
tive fluorescence units were converted to concentration
according to prepared standard, and were corrected for
background fluorescence. The amount of fluorescently-
labelled Aβ42 was calculated as apparent permeability
(Papp) coefficient [ref. Zhao Z 2015 Nat Neurosci; Keaney
J 2015 Sci Adv] and expressed as fold change of control.
Briefly, Aβ42 volume cleared (ΔVc) was calculated using
the equation ΔVc = Clower × Vlower/Cupper, where Cupper and
Clower are fluorescently-labeled Aβ42 concentrations in
the donor and receiving compartments, respectively, and
Vlower is the volume on the basolateral side. The volume
cleared (ΔVc) was plotted against assay time. Permeability
coefficients (P) were calculated by dividing against the
surface area of the filter (1.12 cm2).Immunocytochemistry and cells imaging
Cells were fixed for 15 min at room temperature in a
4 % (w/v) PFA, 4 % (w/v) sucrose, 20 mM NaOH
and 5 mM MgCl2 in PBS, pH 7.4. Cells were perme-
abilized and blocked for 30–60 min at room
temperature in 15 % (w/v) goat serum, 0.3 % (v/v)
Triton X-100, 450 mM NaCl, 20 mM phosphate
buffer, pH 7.4 and incubated at 4 °C overnight with
primary antibodies diluted in blocking buffer. Cover-
slips were mounted onto slides with PBS containing
70 % glycerol and 1 μM DAPI. Representative images
were taken using a confocal microscope Fluoview
FV1000 Olympus IX81 (Center Valley, PA, USA) with an
oil immersion objective (×40 or × 60 × 1.4 NA Plan-
Apochromat; Olympus) using laser excitation at 405, 488
or 594 nm, and processed using Fiji [91]. Alternatively
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BioMap) and acquired with inverted microscope Olympus
IX53 (Center Valley, PA, USA).
Brain homogenate preparation and western blot analysis
Animals were anesthetized and perfused with PBS before
brains were removed, weighted and homogeneted in a
mild hypotonic buffer (50 mM Tris pH 8, 150 mM NaCl,
5 mM EDTA supplemented with phosphatase and prote-
ase inhibitor, EDTA-free, Roche). Supernatants were then
centrifuged for 1 h at 3000 × g to pellet insoluble material,
including insoluble Aβ species. Samples were either frozen
on dry ice or LDS sample buffer (Invitrogen) containg 5 %
β-mercaptoethanol was immediately added. Pellets were
directly resuspended in 20 μl of LDS sample buffer. 10 μl
sample were loaded onto a Bolt 4–12 % Bis-Tris Plus Gels
(Thermo Fisher) for Western Blot evaluation. Samples
were separated using MES buffer and transferred onto a
0.22 μM nitrocellulose membrane (Bio-Rad). Membranes
were washed in TBS-Tween (150 mM NaCl, 50 mM Tris
and 0.1 % (v/v) Tween-20) and incubated for 45 min at
room temperature in blocking solution (5 % milk or 2.5 %
serum bovine albumin in TBST). Membranes were subse-
quently probed overnight at 4 °C with primary antibodies
diluted in TBS-T buffer. Membranes were washed exten-
sively and incubated for 45 min at room temperature with
horseradish peroxidase-conjugated (HRP) secondary anti-
body diluted in TBST buffer. Antibody-specific signals
were detected using enhanced chemiluminescence re-
agents (Clarity Western ECL substrate, Bio-Rad).
Dot blot analysis
Aliquots of supernatant samples (200 μL) were loaded on
nitrocellulose membrane Trans-Blot Transfer Medium
(0.22 μm, Bio-Rad), by vacuum deposition on the Bio-Dot
SF blotting apparatus (Bio-Rad). Serial dilution curves of
Aβ42 synthetic protein were preliminarily run to obtain
non-saturating condition of immunodetection. DB dots
images were analysed by Image Lab™ software (Bio-Rad).
ELISA
Aβ42 levels were determined using specific ELISA kit
(Amyloid-beta (x-42) ELISA IBL, International) following
manufacturer’s instructions. Briefly, 100 μL of sample was
added into the pre-coated plate and was incubated over-
night at 4 °C. After washing each well of the pre-coated
plate, 100 μL of labeled antibody solution was added and
the mixture was incubated for 1 h at 4 °C in the dark.
After washing, chromogen was added and the mixture
was incubated for 30 min at room temperature in the
dark. After the addition of stop solution, the resulting
color was assayed at 450 nm using a microplate absorb-
ance reader (Synergy H4 Synergy™ H4 Microplate Reader,
BioTek).Histological and immunohistochemical analyses
Mice were anesthetized and perfused with 0.9 % saline,
followed by 4 % PFA. The 30 μm cryosections of brain
were blocked in PBS containing 10 % goat serum and
0.1 % Triton X-100 for 1 h at room temperature before
being incubated overnight at 4 °C with primary anti-
bodies. The following day, the slides were rinsed in PBS
and incubated at room temperature for 1 h with second-
ary antibody. The slides were processed using the ABC
detection kit (Vector Laboratories). The presence of the
antigens was revealed using the DAB (diaminobenzidine)
(brown) peroxidase substrate kit (Vector Laboratories).
Immunofluorescence and ThT staining were performed
on brain sections. Brain slices were washed three times
in PBS and incubated for 1 h at room temperature in
blocking solution (3 % BSA). Subsequently, the slides
were washed 3 times and incubated overnight with spe-
cific antibodies. The next day, sections were washed in
PBS and incubated for 2 h at room temperature with
specific fluorochrome-conjugated secondary antibodies
diluted in 3 % BSA in the dark. ThT solution was pre-
pared as described above. Final solution was added to
free floating slides for 1 min and very quickly washed
with 80 % methanol followed by 3 washes with distilled
water. Images were acquired by Virtual Slides micro-
scope (VS120, Olympus). For quantification, both dif-
fuse-plaques and dense-core plaques were considered, as
described in [92]. Small dots and deposits at the slice
edge were not counted. The entire surface of the slice
was examined. For congo red histological staining, slices
were air-dried on glass overnight, then stained with a
0.2 % congo red solution according to [93]. Specimens
were acquired by transmittance polarized light micros-
copy, FITCH filtered epifluorescence. For quantification,
bright field images were analyzed by color segmentation
plugin-ImageJ software (NIH, Bethesda, MD). The entire
area of deposits was considered.
Statistical analysis
Statistical analysis was performed with PRISM software
(Graph-Pad Software, San Diego, CA, USA). Data are
expressed as mean ± SEM. Comparisons between two
groups were performed using Student’s t test or by non-
parametric two-tailed Mann–Whitney U test. For the
comparison of more than two groups, two-way ANOVA
followed by Bonferroni’s post hoc test was used. Differ-
ences were considered significant at *P < 0.05, **P < 0.01,
***P < 0.001.
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